{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:23:05Z","timestamp":1785198185683,"version":"3.55.0"},"reference-count":141,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["HT9425-23-1-1049"],"award-info":[{"award-number":["HT9425-23-1-1049"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA259171"],"award-info":[{"award-number":["R01 CA259171"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.msard.2026.107066","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T01:00:12Z","timestamp":1770685212000},"page":"107066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeting Epstein-Barr virus (EBV) for treatment of multiple sclerosis"],"prefix":"10.1016","volume":"109","author":[{"given":"Samantha S.","family":"Soldan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy E.","family":"Messick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3935-9921","authenticated-orcid":false,"given":"Paul M.","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.msard.2026.107066_bib0001","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1474-4422(22)00471-9","article-title":"Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy","volume":"22","author":"Aloisi","year":"2023","journal-title":"Lancet Neurol."},{"issue":"12","key":"10.1016\/j.msard.2026.107066_bib0002","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1086\/523815","article-title":"Epstein-Barr virus vaccine for the prevention of infectious mononucleosis\u2013and what else?","volume":"196","author":"Balfour","year":"2007","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.msard.2026.107066_bib0003","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.molmed.2019.11.003","article-title":"Epstein-Barr Virus in multiple sclerosis: theory and emerging immunotherapies","volume":"26","author":"Bar-Or","year":"2020","journal-title":"Trends. Mol. Med."},{"issue":"7142","key":"10.1016\/j.msard.2026.107066_bib0004","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nature05762","article-title":"Herpesvirus latency confers symbiotic protection from bacterial infection","volume":"447","author":"Barton","year":"2007","journal-title":"Nature"},{"issue":"48","key":"10.1016\/j.msard.2026.107066_bib0005","doi-asserted-by":"crossref","first-page":"E11379","DOI":"10.1073\/pnas.1810128115","article-title":"Epstein-Barr virus enhances genome maintenance of Kaposi sarcoma-associated herpesvirus","volume":"115","author":"Bigi","year":"2018","journal-title":"Proc. Natl. Acad. Sci. u S. a"},{"issue":"6578","key":"10.1016\/j.msard.2026.107066_bib0006","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.msard.2026.107066_bib0007","first-page":"160","article-title":"Epstein-Barr virus as a leading cause of multiple sclerosis: mechanisms and implications","volume":"19","author":"Bjornevik","year":"2023","journal-title":"Nat. Rev. Neurol."},{"issue":"7517","key":"10.1016\/j.msard.2026.107066_bib0008","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"Cancer Genome Atlas Research","year":"2014","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.msard.2026.107066_bib0009","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1086\/515290","article-title":"Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype","volume":"177","author":"Chodosh","year":"1998","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.msard.2026.107066_bib0010","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1158\/1078-0432.CCR-24-2814","article-title":"First-in-Human clinical trial of a small-molecule EBNA1 inhibitor, VK-2019, in patients with Epstein-Barr-positive nasopharyngeal cancer, with pharmacokinetic and pharmacodynamic studies","volume":"31","author":"Colevas","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.msard.2026.107066_bib0011","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41579-020-00448-w","article-title":"The structural basis of herpesvirus entry","volume":"19","author":"Connolly","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"issue":"9","key":"10.1016\/j.msard.2026.107066_bib0012","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1474-4422(21)00250-7","article-title":"BTK inhibitors as potential therapies for multiple sclerosis","volume":"20","author":"Correale","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107066_bib0013","article-title":"EBV and autoimmunity","author":"Cortese","year":"2025","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"2","key":"10.1016\/j.msard.2026.107066_bib0014","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.tim.2019.09.002","article-title":"Control of viral latency by episome maintenance proteins","volume":"28","author":"De Leo","year":"2020","journal-title":"Trends. Microbiol."},{"issue":"5","key":"10.1016\/j.msard.2026.107066_bib0015","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms11051262","article-title":"Markers of Epstein-Barr Virus infection in patients with multiple sclerosis","volume":"11","author":"Debuysschere","year":"2023","journal-title":"Microorganisms"},{"issue":"1","key":"10.1016\/j.msard.2026.107066_bib0016","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis - a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2026.107066_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105444","article-title":"In the era of antiviral trials for MS, the answer lies in the details","volume":"82","author":"Drosu","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"22","key":"10.1016\/j.msard.2026.107066_bib0018","doi-asserted-by":"crossref","first-page":"12368","DOI":"10.1073\/pnas.2002392117","article-title":"Tenofovir prodrugs potently inhibit Epstein-Barr virus lytic DNA replication by targeting the viral DNA polymerase","volume":"117","author":"Drosu","year":"2020","journal-title":"Proc. Natl. Acad. Sci. u S. a"},{"issue":"5","key":"10.1016\/j.msard.2026.107066_bib0019","first-page":"380","article-title":"Immunological responses to the combination of EBNA1 and LMP2 in mice","volume":"32","author":"Du","year":"2019","journal-title":"Biomed. Environ. Sci."},{"issue":"1A","key":"10.1016\/j.msard.2026.107066_bib0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0002-9343(82)90055-9","article-title":"Mechanism of action and selectivity of acyclovir","volume":"73","author":"Elion","year":"1982","journal-title":"Am. J. Med."},{"issue":"13","key":"10.1016\/j.msard.2026.107066_bib0021","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1073\/pnas.0306482101","article-title":"Inhibition of Epstein-Barr virus-induced growth proliferation by a nuclear antigen EBNA2-TAT peptide","volume":"101","author":"Farrell","year":"2004","journal-title":"Proc. Natl. Acad. Sci. u S. a"},{"key":"10.1016\/j.msard.2026.107066_bib0022","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-pathmechdis-012418-013023","article-title":"Epstein-Barr virus and cancer","volume":"14","author":"Farrell","year":"2019","journal-title":"Annu Rev. Pathol."},{"key":"10.1016\/j.msard.2026.107066_bib0023","first-page":"3","article-title":"Ebna1","volume":"391","author":"Frappier","year":"2015","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"4","key":"10.1016\/j.msard.2026.107066_bib0024","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1615\/CritRevOncog.2020032954","article-title":"Epstein-Barr virus and astrocytoma","volume":"24","author":"Freixo","year":"2019","journal-title":"Crit. Rev. Oncog."},{"key":"10.1016\/j.msard.2026.107066_bib0025","article-title":"The Epstein-Barr Virus in classical Hodgkin Lymphoma: pathogenesis, immunobiology, and therapeutic implications","author":"Gandhi","year":"2025","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"4","key":"10.1016\/j.msard.2026.107066_bib0026","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10822-016-9899-y","article-title":"Computational analysis of EBNA1 \"druggability\" suggests novel insights for Epstein-Barr virus inhibitor design","volume":"30","author":"Gianti","year":"2016","journal-title":"J. Comput. Aided. Mol. Des."},{"issue":"9","key":"10.1016\/j.msard.2026.107066_bib0027","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1093\/brain\/awaf170","article-title":"The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis","volume":"148","author":"Giovannoni","year":"2025","journal-title":"Brain"},{"key":"10.1016\/j.msard.2026.107066_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1575653","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy","volume":"16","author":"Glenn","year":"2025","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107066_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2025.578758","article-title":"Epstein-Barr virus reactivation is associated with altered immune cell profiles in peripheral blood and cerebrospinal fluid of treatment-naive multiple sclerosis patients","volume":"409","author":"Gouzouasis","year":"2025","journal-title":"J. Neuroimmunol."},{"issue":"8","key":"10.1016\/j.msard.2026.107066_bib0030","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/cti.2016.48","article-title":"Prospective studies of infectious mononucleosis in university students","volume":"5","author":"Grimm","year":"2016","journal-title":"Clin. Transl. Immunology."},{"issue":"5","key":"10.1016\/j.msard.2026.107066_bib0031","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41588-018-0102-3","article-title":"Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity","volume":"50","author":"Harley","year":"2018","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.msard.2026.107066_bib0032","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1177\/0961203306070009","article-title":"The curiously suspicious: a role for Epstein-Barr virus in lupus","volume":"15","author":"Harley","year":"2006","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.msard.2026.107066_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192109","article-title":"Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells","volume":"13","author":"Hassani","year":"2018","journal-title":"PLoS. One"},{"issue":"5","key":"10.1016\/j.msard.2026.107066_bib0034","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s40120-025-00784-0","article-title":"Five-year safety and efficacy outcomes with Ofatumumab in patients with relapsing multiple sclerosis","volume":"14","author":"Hauser","year":"2025","journal-title":"Neurol. Ther."},{"issue":"5","key":"10.1016\/j.msard.2026.107066_bib0035","first-page":"1491","article-title":"The development of Ofatumumab, a fully Human anti-CD20 monoclonal antibody for practical use in relapsing","volume":"12","author":"Hauser","year":"2023","journal-title":"Multiple Sclerosis Treatment. Neurol. Ther."},{"issue":"1","key":"10.1016\/j.msard.2026.107066_bib0036","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011040","article-title":"New insight into Epstein-Barr virus infection using models of stratified epithelium","volume":"19","author":"Hayman","year":"2023","journal-title":"PLoS. Pathog."},{"issue":"5","key":"10.1016\/j.msard.2026.107066_bib0037","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1200\/JCO.20.01709","article-title":"Adoptive T-cell therapy for Epstein-Barr virus-related lymphomas","volume":"39","author":"Heslop","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.msard.2026.107066_bib0038","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1101\/gr.264705.120","article-title":"Epstein-Barr virus nuclear antigen 2 extensively rewires the human chromatin landscape at autoimmune risk loci","volume":"31","author":"Hong","year":"2021","journal-title":"Genome Res."},{"issue":"6","key":"10.1016\/j.msard.2026.107066_bib0039","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/0008-5472.CAN-12-2448","article-title":"Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients","volume":"73","author":"Hui","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.msard.2026.107066_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1556196","article-title":"CXCR3 inhibitors for therapeutic interventions: current status and perspectives","volume":"16","author":"Huo","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"16","key":"10.1016\/j.msard.2026.107066_bib0041","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1021\/acschemneuro.1c00350","article-title":"Identification of potential inhibitors against Epstein-Barr Virus nuclear antigen 1 (EBNA1): an insight from docking and molecular dynamic simulations","volume":"12","author":"Jakhmola","year":"2021","journal-title":"ACS. Chem. Neurosci."},{"issue":"49","key":"10.1016\/j.msard.2026.107066_bib0042","doi-asserted-by":"crossref","first-page":"6517","DOI":"10.1039\/C4CC01589D","article-title":"EBNA1-specific luminescent small molecules for the imaging and inhibition of latent EBV-infected tumor cells","volume":"50","author":"Jiang","year":"2014","journal-title":"Chem. Commun."},{"issue":"19","key":"10.1016\/j.msard.2026.107066_bib0043","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.7150\/thno.26823","article-title":"EBNA1-targeted inhibitors: novel approaches for the treatment of Epstein-Barr virus-associated cancers","volume":"8","author":"Jiang","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.msard.2026.107066_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102332","article-title":"Epstein Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model","volume":"106","author":"Jog","year":"2020","journal-title":"J. Autoimmun."},{"issue":"4","key":"10.1016\/j.msard.2026.107066_bib0045","first-page":"325","article-title":"Seroreactivity against lytic, latent and possible cross-reactive EBV antigens appears on average 10 years before MS induced preclinical neuroaxonal damage","volume":"95","author":"Jons","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.msard.2026.107066_bib0046","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1128\/JVI.01628-10","article-title":"Roscovitine inhibits EBNA1 serine 393 phosphorylation, nuclear localization, transcription, and episome maintenance","volume":"85","author":"Kang","year":"2011","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.msard.2026.107066_bib0047","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1474-4422(14)70028-6","article-title":"Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"13","author":"Kappos","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107066_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103572","article-title":"The interaction of Epstein-Barr virus encoded transcription factor EBNA2 with multiple sclerosis risk loci is dependent on the risk genotype","volume":"71","author":"Keane","year":"2021","journal-title":"EBioMedicine"},{"issue":"16","key":"10.1016\/j.msard.2026.107066_bib0049","doi-asserted-by":"crossref","first-page":"10709","DOI":"10.1128\/JVI.79.16.10709-10717.2005","article-title":"Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis","volume":"79","author":"Kelly","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.msard.2026.107066_bib0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.549842","article-title":"Natalizumab in multiple sclerosis treatment: from biological effects to Immune monitoring","volume":"11","author":"Khoy","year":"2020","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.msard.2026.107066_bib0051","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.bbrc.2012.06.095","article-title":"Small molecule and peptide-mediated inhibition of Epstein-Barr virus nuclear antigen 1 dimerization","volume":"424","author":"Kim","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.msard.2026.107066_bib0052","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1128\/jvi.71.3.1766-1775.1997","article-title":"Dominant-negative inhibitors of EBNA-1 of Epstein-Barr virus","volume":"71","author":"Kirchmaier","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.msard.2026.107066_bib0053","article-title":"Lenacapavir: A twice-yearly injectable for HIV preexposure prophylaxis","author":"Koren","year":"2025","journal-title":"Ann. Pharmacother"},{"issue":"1","key":"10.1016\/j.msard.2026.107066_bib0054","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12915-020-00785-5","article-title":"A tissue level atlas of the healthy human virome","volume":"18","author":"Kumata","year":"2020","journal-title":"BMC. Biol."},{"issue":"8083","key":"10.1016\/j.msard.2026.107066_bib0055","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41586-025-09378-0","article-title":"EBV induces CNS homing of B cells attracting inflammatory T cells","volume":"646","author":"Laderach","year":"2025","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.msard.2026.107066_bib0056","doi-asserted-by":"crossref","first-page":"e1438","DOI":"10.1002\/cti2.1438","article-title":"Roadmap for understanding mechanisms on how Epstein-Barr virus triggers multiple sclerosis and for translating these discoveries in clinical trials","volume":"12","author":"Lanz","year":"2023","journal-title":"Clin. Transl. Immunology."},{"key":"10.1016\/j.msard.2026.107066_bib0057","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.msard.2017.05.009","article-title":"Epstein-Barr virus and multiple sclerosis: updating Pender's hypothesis","volume":"16","author":"Laurence","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2026.107066_bib0058","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.msard.2026.107066_bib0059","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.antiviral.2014.01.018","article-title":"Small molecule inhibition of Epstein-Barr virus nuclear antigen-1 DNA binding activity interferes with replication and persistence of the viral genome","volume":"104","author":"Lee","year":"2014","journal-title":"Antiviral Res."},{"issue":"2","key":"10.1016\/j.msard.2026.107066_bib0060","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/(SICI)1099-1654(200003\/04)10:2<83::AID-RMV262>3.0.CO;2-T","article-title":"EBNA-1: a protein pivotal to latent infection by Epstein-Barr virus","volume":"10","author":"Leight","year":"2000","journal-title":"Rev. Med. Virol."},{"issue":"7957","key":"10.1016\/j.msard.2026.107066_bib0061","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41586-023-05923-x","article-title":"Chromosomal fragile site breakage by EBV-encoded EBNA1 at clustered repeats","volume":"616","author":"Li","year":"2023","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.msard.2026.107066_bib0062","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1517\/17460441.2010.524640","article-title":"Development of drugs for Epstein-Barr virus using high-throughput in silico virtual screening","volume":"5","author":"Li","year":"2010","journal-title":"Expert. Opin. Drug Discov."},{"issue":"4","key":"10.1016\/j.msard.2026.107066_bib0063","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010126","article-title":"Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening","volume":"5","author":"Li","year":"2010","journal-title":"PLoS. One"},{"issue":"9","key":"10.1016\/j.msard.2026.107066_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110581","article-title":"A small molecule that selectively inhibits the growth of Epstein-Barr virus-latently infected cancer cells","volume":"27","author":"Li","year":"2024","journal-title":"iScience"},{"issue":"8075","key":"10.1016\/j.msard.2026.107066_bib0066","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41586-025-09166-w","article-title":"R9AP is a common receptor for EBV infection in epithelial cells and B cells","volume":"644","author":"Li","year":"2025","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.msard.2026.107066_bib0064","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40263-024-01153-5","article-title":"Repurposing licensed drugs with activity against Epstein-Barr virus for treatment of multiple sclerosis: A systematic approach","volume":"39","author":"Li","year":"2025","journal-title":"CNS. Drugs"},{"issue":"1","key":"10.1016\/j.msard.2026.107066_bib0067","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2447141","article-title":"The novel CD16A\/anti-CD3 bifunctional protein, eCD16A\/anti-CD3-BFP, redirects T cell cytotoxicity toward antibody-bound target cells","volume":"21","author":"Lin","year":"2025","journal-title":"Hum. Vaccin. ImmunOther"},{"key":"10.1016\/j.msard.2026.107066_bib0069","article-title":"Epstein-Barr virus and multiple sclerosis: A mechanism comes into focus","volume":"105","author":"Lindsey","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2026.107066_bib0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/NEN.0b013e31827bfc62","article-title":"B-cell enrichment and Epstein-Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis","volume":"72","author":"Magliozzi","year":"2013","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.107066_bib0071","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41419-024-06602-z","article-title":"Disrupting pro-survival and inflammatory pathways with dimethyl fumarate sensitizes chronic lymphocytic leukemia to cell death","volume":"15","author":"Mantione","year":"2024","journal-title":"Cell Death. Dis."},{"issue":"8","key":"10.1016\/j.msard.2026.107066_bib0072","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: A review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMa"},{"key":"10.1016\/j.msard.2026.107066_bib0073","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2025.105854","article-title":"Epstein-Barr virus (EBV) infection and its sequelae in the immunocompetent host","volume":"180","author":"Meirhaeghe","year":"2025","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.msard.2026.107066_bib0074","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/978-3-031-65187-8_20","article-title":"Antiviral agents: structural basis of action and rational design","volume":"105","author":"Menendez-Arias","year":"2024","journal-title":"SubCell Biochem."},{"issue":"9","key":"10.1016\/j.msard.2026.107066_bib0075","doi-asserted-by":"crossref","first-page":"7722","DOI":"10.1128\/JVI.73.9.7722-7733.1999","article-title":"Epstein-Barr virus infection of human astrocyte cell lines","volume":"73","author":"Menet","year":"1999","journal-title":"J. Virol."},{"issue":"482","key":"10.1016\/j.msard.2026.107066_bib0076","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5612","article-title":"Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth","volume":"11","author":"Messick","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.msard.2026.107066_bib0077","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25071760","article-title":"Biophysical screens identify fragments that bind to the viral DNA-binding proteins EBNA1 and LANA","volume":"25","author":"Messick","year":"2020","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.msard.2026.107066_bib0078","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200149","article-title":"EBNA1 Inhibitors block proliferation of spontaneous lymphoblastoid cell lines from patients with multiple sclerosis and healthy controls","volume":"10","author":"Monaco","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.msard.2026.107066_bib0079","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1212\/NXI.0000000000000466","article-title":"Molecular signature of Epstein-Barr virus infection in MS brain lesions","volume":"5","author":"Moreno","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"32","key":"10.1016\/j.msard.2026.107066_bib0080","doi-asserted-by":"crossref","first-page":"16046","DOI":"10.1073\/pnas.1901314116","article-title":"Epstein-Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection","volume":"116","author":"Mrozek-Gorska","year":"2019","journal-title":"Proc. Natl. Acad. Sci. u S. a"},{"issue":"2","key":"10.1016\/j.msard.2026.107066_bib0081","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1097-2765(02)00465-3","article-title":"Structure of the Epstein-Barr virus gp42 protein bound to the MHC class II receptor HLA-DR1","volume":"9","author":"Mullen","year":"2002","journal-title":"Mol. Cell"},{"issue":"5","key":"10.1016\/j.msard.2026.107066_bib0082","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nchembio.1479","article-title":"G-quadruplexes regulate Epstein-Barr virus-encoded nuclear antigen 1 mRNA translation","volume":"10","author":"Murat","year":"2014","journal-title":"Nat. Chem. Biol."},{"issue":"21","key":"10.1016\/j.msard.2026.107066_bib0083","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01121-17","article-title":"Crystal structure of the DNA-binding domain of Human herpesvirus 6A immediate early protein 2","volume":"91","author":"Nishimura","year":"2017","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.msard.2026.107066_bib0084","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s12272-009-1512-7","article-title":"Maintenance of the viral episome is essential for the cell survival of an Epstein-Barr virus positive gastric carcinoma cell line","volume":"32","author":"Oh","year":"2009","journal-title":"Arch. Pharm. Res."},{"issue":"3","key":"10.1016\/j.msard.2026.107066_bib0085","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10048-024-00764-w","article-title":"Hitting Epstein Barr virus where it hurts: computational methods exploration for siRNA therapy in alleviating Epstein Barr virus-induced multiple sclerosis","volume":"25","author":"Ojo","year":"2024","journal-title":"Neurogenetics"},{"issue":"11","key":"10.1016\/j.msard.2026.107066_bib0086","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2425670122","article-title":"Epstein-Barr virus and the immune microenvironment in multiple sclerosis: insights from high-dimensional brain tissue imaging","volume":"122","author":"Orr","year":"2025","journal-title":"Proc. Natl. Acad. Sci. u S. a"},{"key":"10.1016\/j.msard.2026.107066_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117386","article-title":"Emerging drugs for Epstein-Barr virus associated-diseases","volume":"287","author":"Oumata","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.msard.2026.107066_bib0088","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01723-19","article-title":"First days in the life of naive Human B lymphocytes infected with Epstein-Barr Virus","volume":"10","author":"Pich","year":"2019","journal-title":"mBio"},{"issue":"2","key":"10.1016\/j.msard.2026.107066_bib0089","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/AAC.00615-10","article-title":"Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management","volume":"55","author":"Piret","year":"2011","journal-title":"Antimicrob. Agents Chemother"},{"issue":"12","key":"10.1016\/j.msard.2026.107066_bib0090","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.70722","article-title":"EBV-positive diffuse large B-cell lymphoma (DLBCL): an assessment and a roadmap","volume":"97","author":"Porcu","year":"2025","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.msard.2026.107066_bib0091","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/B978-0-12-800098-4.00006-4","article-title":"Dynamic Epstein-Barr virus gene expression on the path to B-cell transformation","volume":"88","author":"Price","year":"2014","journal-title":"Adv. Virus. Res."},{"issue":"14","key":"10.1016\/j.msard.2026.107066_bib0092","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0b013e3181d865a1","article-title":"Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis","volume":"74","author":"Sargsyan","year":"2010","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2026.107066_bib0093","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1128\/JVI.78.8.3941-3952.2004","article-title":"Identification of Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) target proteins by proteome analysis: activation of EBNA2 in conditionally immortalized B cells reflects early events after infection of primary B cells by EBV","volume":"78","author":"Schlee","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.msard.2026.107066_bib0094","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2024.578314","article-title":"EBV infected cells in the multiple sclerosis brain express PD-L1: how the virus and its niche may escape immune surveillance","volume":"389","author":"Serafini","year":"2024","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2026.107066_bib0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578036","article-title":"Tissue-resident memory T cells in the multiple sclerosis brain and their relationship to Epstein-Barr virus infected B cells","volume":"376","author":"Serafini","year":"2023","journal-title":"J. Neuroimmunol."},{"issue":"7","key":"10.1016\/j.msard.2026.107066_bib0096","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/NEN.0b013e3181e332ec","article-title":"Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation","volume":"69","author":"Serafini","year":"2010","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2026.107066_bib0097","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/bloodadvances.2024015157","article-title":"Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies","volume":"9","author":"Shahid","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.msard.2026.107066_bib0098","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3389\/fonc.2019.00713","article-title":"The global landscape of EBV-associated tumors","volume":"9","author":"Shannon-Lowe","year":"2019","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.msard.2026.107066_bib0099","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41584-023-01002-7","article-title":"TNF and TNF receptors as therapeutic targets for rheumatic diseases and beyond","volume":"19","author":"Siegmund","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"10.1016\/j.msard.2026.107066_bib0100","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1600-0404.2010.01410.x","article-title":"EBNA1 and LMP1 variants in multiple sclerosis cases and controls","volume":"124","author":"Simon","year":"2011","journal-title":"Acta Neurol. Scand."},{"issue":"5","key":"10.1016\/j.msard.2026.107066_bib0101","first-page":"1041","article-title":"Multiple sclerosis and subsequent Human Immunodeficiency Virus infection: A case with the rare comorbidity, focus on novel treatment issues and review of the literature","volume":"31","author":"Skarlis","year":"2017","journal-title":"In. Vivo"},{"issue":"9240","key":"10.1016\/j.msard.2026.107066_bib0102","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S0140-6736(00)02879-8","article-title":"Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system","volume":"356","author":"Slobod","year":"2000","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.msard.2026.107066_bib0103","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.1128\/JVI.00239-09","article-title":"Acquisition of polyfunctionality by Epstein-Barr virus-specific CD8+ T cells correlates with increased resistance to galectin-1-mediated suppression","volume":"83","author":"Smith","year":"2009","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.msard.2026.107066_bib0104","doi-asserted-by":"crossref","first-page":"e1444","DOI":"10.1002\/cti2.1444","article-title":"Adoptive T-cell therapy targeting Epstein-Barr virus as a treatment for multiple sclerosis","volume":"12","author":"Smith","year":"2023","journal-title":"Clin. Transl. Immunology."},{"issue":"1","key":"10.1016\/j.msard.2026.107066_bib0105","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41579-022-00770-5","article-title":"Epstein-Barr virus and multiple sclerosis","volume":"21","author":"Soldan","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"issue":"6","key":"10.1016\/j.msard.2026.107066_bib0106","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009618","article-title":"Epigenetic plasticity enables CNS-trafficking of EBV-infected B lymphocytes","volume":"17","author":"Soldan","year":"2021","journal-title":"PLoS. Pathog."},{"issue":"6","key":"10.1016\/j.msard.2026.107066_bib0107","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41564-024-01699-6","article-title":"Multiple sclerosis patient-derived spontaneous B cells have distinct EBV and host gene expression profiles in active disease","volume":"9","author":"Soldan","year":"2024","journal-title":"Nat. Microbiol."},{"issue":"12","key":"10.1016\/j.msard.2026.107066_bib0108","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.188543","article-title":"Early multiple sclerosis activity associated with TBX21+CD21loCXCR3+ B cell expansion resembling EBV-induced phenotypes","volume":"10","author":"SoRelle","year":"2025","journal-title":"JCI. Insight."},{"issue":"1","key":"10.1016\/j.msard.2026.107066_bib0109","doi-asserted-by":"crossref","DOI":"10.1128\/mmbr.00119-23","article-title":"Multiple sclerosis and infection: history, EBV, and the search for mechanism","volume":"89","author":"SoRelle","year":"2025","journal-title":"Microbiol. Mol. Biol. Rev."},{"issue":"1","key":"10.1016\/j.msard.2026.107066_bib0110","doi-asserted-by":"crossref","DOI":"10.3390\/v17010110","article-title":"Targeting EBV episome for anti-cancer therapy: emerging strategies and challenges","volume":"17","author":"Sugiokto","year":"2025","journal-title":"Viruses"},{"issue":"36","key":"10.1016\/j.msard.2026.107066_bib0111","doi-asserted-by":"crossref","first-page":"33353","DOI":"10.1074\/jbc.M104535200","article-title":"Targeting of EBNA1 for rapid intracellular degradation overrides the inhibitory effects of the gly-Ala repeat domain and restores CD8+ T cell recognition","volume":"276","author":"Tellam","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.msard.2026.107066_bib0112","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004423","article-title":"mRNA structural constraints on EBNA1 synthesis impact on in vivo antigen presentation and early priming of CD8+ T cells","volume":"10","author":"Tellam","year":"2014","journal-title":"PLoS. Pathog."},{"issue":"20","key":"10.1016\/j.msard.2026.107066_bib0113","doi-asserted-by":"crossref","first-page":"eadg3032","DOI":"10.1126\/sciadv.adg3032","article-title":"Cross-reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosis","volume":"9","author":"Thomas","year":"2023","journal-title":"Sci. Adv."},{"issue":"6","key":"10.1016\/j.msard.2026.107066_bib0114","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012177","article-title":"Heightened Epstein-Barr virus immunity and potential cross-reactivities in multiple sclerosis","volume":"20","author":"Thomas","year":"2024","journal-title":"PLoS. Pathog."},{"issue":"5","key":"10.1016\/j.msard.2026.107066_bib0115","doi-asserted-by":"crossref","first-page":"e1451","DOI":"10.1002\/cti2.1451","article-title":"Epstein-Barr virus and multiple sclerosis: moving from questions of association to questions of mechanism","volume":"12","author":"Thomas","year":"2023","journal-title":"Clin. Transl. Immunology."},{"key":"10.1016\/j.msard.2026.107066_bib0116","first-page":"151","article-title":"EBV persistence\u2013introducing the virus","volume":"390","author":"Thorley-Lawson","year":"2015","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"12","key":"10.1016\/j.msard.2026.107066_bib0117","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nrmicro2015","article-title":"The curious case of the tumour virus: 50 years of Burkitt's lymphoma","volume":"6","author":"Thorley-Lawson","year":"2008","journal-title":"Nat. Rev. Microbiol."},{"issue":"13","key":"10.1016\/j.msard.2026.107066_bib0118","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMra032015","article-title":"Persistence of the Epstein-Barr virus and the origins of associated lymphomas","volume":"350","author":"Thorley-Lawson","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107066_bib0119","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102569","article-title":"Tenofovir as a treatment option for multiple sclerosis","volume":"46","author":"Torkildsen","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107066_bib0120","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1098\/rstb.2016.0270","article-title":"Epstein-Barr virus infection and nasopharyngeal carcinoma","volume":"372","author":"Tsao","year":"2017","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"issue":"2","key":"10.1016\/j.msard.2026.107066_bib0121","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147567","article-title":"Identifying patient-specific Epstein-Barr nuclear antigen-1 genetic variation and potential autoreactive targets relevant to multiple sclerosis pathogenesis","volume":"11","author":"Tschochner","year":"2016","journal-title":"PLoS. One"},{"issue":"1","key":"10.1016\/j.msard.2026.107066_bib0122","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1212\/WNL.0b013e31823ed057","article-title":"Association of innate immune activation with latent Epstein-Barr virus in active MS lesions","volume":"78","author":"Tzartos","year":"2012","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2026.107066_bib0123","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1007\/s00415-022-11072-4","article-title":"Environmental risk factors in multiple sclerosis: bridging mendelian randomization and observational studies","volume":"269","author":"Vandebergh","year":"2022","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.107066_bib0124","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12974-017-1049-5","article-title":"Transcriptional profile and Epstein-Barr virus infection status of laser-cut immune infiltrates from the brain of patients with progressive multiple sclerosis","volume":"15","author":"Veroni","year":"2018","journal-title":"J. Neuroinflammation."},{"issue":"12","key":"10.1016\/j.msard.2026.107066_bib0125","first-page":"591","article-title":"Epstein-Barr virus and the origin of Hodgkin lymphoma","volume":"33","author":"Vockerodt","year":"2014","journal-title":"Chin. J. Cancer"},{"issue":"6","key":"10.1016\/j.msard.2026.107066_bib0126","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200460","article-title":"Epstein-Barr Virus in multiple sclerosis: past, present, and future","volume":"12","author":"Wahbeh","year":"2025","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"36","key":"10.1016\/j.msard.2026.107066_bib0127","doi-asserted-by":"crossref","first-page":"13157","DOI":"10.1073\/pnas.1410785111","article-title":"RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection","volume":"111","author":"Wang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. u S. a"},{"issue":"9","key":"10.1016\/j.msard.2026.107066_bib0128","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/acn3.50862","article-title":"Environmental and genetic risk factors for MS: an integrated review","volume":"6","author":"Waubant","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2026.107066_bib0129","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1093\/brain\/awp200","article-title":"Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain","volume":"132","author":"Willis","year":"2009","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.msard.2026.107066_bib0130","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00572-24","article-title":"Polymerase theta is a synthetic lethal target for killing Epstein-Barr virus lymphomas","volume":"98","author":"Willman","year":"2024","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.msard.2026.107066_bib0131","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","article-title":"Nasopharyngeal carcinoma: an evolving paradigm","volume":"18","author":"Wong","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.msard.2026.107066_bib0132","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00394-22","article-title":"Epstein-Barr Virus genome deletions in Epstein-Barr virus-positive T\/NK cell lymphoproliferative diseases","volume":"96","author":"Wongwiwat","year":"2022","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.msard.2026.107066_bib0133","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202500007","article-title":"EBNA1 Targeted ultra-small near-infrared persistent luminescent nano-inhibitor for theranostics of EBV-associated cancer","volume":"14","author":"Xie","year":"2025","journal-title":"Adv. Healthc. Mater."},{"issue":"12","key":"10.1016\/j.msard.2026.107066_bib0134","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1111\/j.1349-7006.2011.02098.x","article-title":"DNA ligand designed to antagonize EBNA1 represses Epstein-Barr virus-induced immortalization","volume":"102","author":"Yasuda","year":"2011","journal-title":"Cancer Sci."},{"issue":"2","key":"10.1016\/j.msard.2026.107066_bib0135","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.virol.2005.11.021","article-title":"siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells","volume":"346","author":"Yin","year":"2006","journal-title":"Virology"},{"issue":"824","key":"10.1016\/j.msard.2026.107066_bib0136","doi-asserted-by":"crossref","first-page":"eady0210","DOI":"10.1126\/scitranslmed.ady0210","article-title":"Epstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells in systemic lupus erythematosus","volume":"17","author":"Younis","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.msard.2026.107066_bib0137","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.virusres.2017.04.019","article-title":"Suppression of Epstein-Barr virus DNA load in latently infected nasopharyngeal carcinoma cells by CRISPR\/Cas9","volume":"244","author":"Yuen","year":"2018","journal-title":"Virus. Res."},{"issue":"2","key":"10.1016\/j.msard.2026.107066_bib0138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41564-017-0080-8","article-title":"Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry","volume":"3","author":"Zhang","year":"2018","journal-title":"Nat. Microbiol."},{"issue":"11","key":"10.1016\/j.msard.2026.107066_bib0139","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/s41564-025-02067-8","article-title":"Desmocollin 2 is a dominant entry receptor for Epstein-Barr virus infection of epithelial cells","volume":"10","author":"Zhang","year":"2025","journal-title":"Nat. Microbiol."},{"issue":"5","key":"10.1016\/j.msard.2026.107066_bib0140","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines13050478","article-title":"EBV vaccines in the prevention and treatment of nasopharyngeal carcinoma","volume":"13","author":"Zhang","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.msard.2026.107066_bib0141","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.147382","article-title":"Targeted delivery and pro-apoptotic efficacy of an Epstein-Barr virus nuclear antigen 1-specific affibody in EBV-infected cells in vitro","volume":"328","author":"Zhou","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"2","key":"10.1016\/j.msard.2026.107066_bib0142","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1021\/acsami.4c20023","article-title":"Intelligent hierarchical targeting near-infrared persistent luminescence nanosystem for improved nuclear delivery and simultaneous visualization\/therapy of EBV-associated cancer","volume":"17","author":"Zhu","year":"2025","journal-title":"ACS. Appl. Mater. Interfaces."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:23:04Z","timestamp":1781526184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826001021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":141,"alternative-id":["S2211034826001021"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107066","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting Epstein-Barr virus (EBV) for treatment of multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107066"}}